Traveler’s Diarrhea – “Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020” report by DelveInsight offers comprehensive insights on marketed and Phase III products for Traveler’s Diarrhea.
Global API Manufacturers of marketed products for Traveler’s Diarrhea coverage of API manufacturers for Traveler’s Diarrhea marketed products spanning across United States, Europe, China and India.
The manufacturer’s details include manufacturers name along with their location Emerging Phase III products for Traveler’s Diarrhea descriptive Phase III product profiles for Traveler’s Diarrhea including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also, their forecasted global sales are provided til 2023.
Traveler’s Diarrhea treatment Market
The Traveler’s Diarrhea Treatment Market comprises of anti-motility drugs or Antidiarrheal drugs (also known as symptomatic therapy) including bismuth subsalicylate and Synthetic opiates such as loperamide and diphenoxylate, with ciprofloxacin, ofloxacin, norfloxacin and levofloxacin and Dukarol (Vaccine) dominating the market as the first line of therapy.
The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023. It further provides the marketed products API manufacturer details for the United States, Europe, China, and India.
The report also covers the emerging Phase III pipeline assets for Traveler’s Diarrhea including their detailed product profiles.
Traveler’s Diarrhea Pipeline Drugs
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Traveler’s Diarrhea key players involved in developing targeted therapeutics.
The late-stage product Bismuth Subsalicylate has emerged as a promising option to enter the market in 2021 for Traveler’s Diarrhea. Another mid-stage product Etvax is a vaccine against diarrheal disease caused by ETEC expected to enter the market by 2023.
Scope of the report
- Comprehensive understanding of Traveler’s Diarrhea marketed and emerging (Phase III) products
- Details for Traveler’s Diarrhea marketed drugs to devise API procurement strategy for generic development
- Developmental timelines around marketed drug patents for the major markets- US and EU
- Current and future growth of marketed Traveler’s Diarrhea therapeutics through their historical and forecasted sales
- Analyzed future sales trends of emerging Phase III Traveler’s Diarrhea therapeutics through their forecasted sales
- Products for target finding, drug repurposing, and precision medicine
Table of Contents
1. Report Introduction
2. Traveler’s Diarrhea
3. Comparative Analysis of Marketed and Emerging Products
5. Report Methodology
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Address:304 S. Jones Blvd #2432
Country: United States